Glaukos Corporation (GKOS)
GKOS trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1192448/000119312526061944/0001193125-26-061944-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GKOS on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001192448 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $507.4M |
| Net income | -$187.7M |
| Operating income | -$199.6M |
| Net margin | -37.0% |
| Operating margin | -39.3% |
| Revenue growth | +32.3% |
| Cash | $90.8M |
| Total assets | $893.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 28.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-28 |
| Cash and burn | $162.3M cash; operating cash flow $11.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 59,196,870 (2026-10-26); 57,434,740 a year earlier; 48,799,581 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Irvine, California, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $69.1M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $211.0M | $2.0M | $38.6M | $162.3M | No debt tags | $690.3M | 10-Q 2026-10-28 |
| Q2 2026 2026-06-30 | $185.6M | -$18.4M | $14.8M | $114.5M | No debt tags | $612.8M | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $150.6M | -$19.8M | -$12.5M | $104.2M | No debt tags | $551.3M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $143.1M | -$133.7M | $6.8M | $90.8M | No debt tags | $507.4M | 10-K 2026-02-23 |
| Q3 2025 2025-09-30 | $133.5M | -$16.2M | -$10.1M | $98.2M | No debt tags | $469.8M | 10-Q 2026-10-28 |
| Q2 2025 2025-06-30 | $124.1M | -$19.7M | $7.0M | $100.8M | No debt tags | $433.0M | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $106.7M | -$18.1M | -$18.5M | $114.3M | No debt tags | $404.5M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $105.5M | -$33.6M | $507K | $169.6M | No debt tags | $383.5M | 10-K 2026-02-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2019-10-17 |
| Latest annual report | 10-K | 2026-02-23 |
| Latest quarterly / interim | 10-Q | 2026-10-28 |
| Latest current report | 8-K | 2026-11-06 |
| Latest proxy | DEFA14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 1,020 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.5% |
| 1 month | +48.5% |
| 3 months | +29.7% |
| Year to date | +117.6% |
| 1 year | +167.6% |
| From 52-week high | -0.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
| BAX | Baxter International Inc. | $25.54 | -1.05% | $13.2B |
| PEN | Penumbra Inc. | $320.62 | -0.09% | $12.6B |
| PODD | Insulet Corporation | $145.29 | -4.72% | $10.1B |
| GMED | Globus Medical Inc. | $70.50 | -2.27% | $9.3B |
| WST | West Pharmaceutical Services Inc. | $417.80 | +0.33% | $29.1B |
| DXCM | DexCom Inc. | $81.61 | -2.06% | $30.4B |
| RMD | ResMed Inc. | $238.19 | -0.56% | $33.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier